匹多莫德分散片联合0.1%他克莫司软膏治疗白癜风的临床疗效

Clinical effect of pidotimod dispersible tablets combined with 0.1% tacrolimus ointment in treating vitiligo

目的探讨匹多莫德分散片联合0.1%他克莫司软膏治疗白癜风的临床疗效。方法选取贵阳市妇幼保健院2011年3月—2014年3月收治的白癜风患者140例,随机分为对照组和研究组,各70例。患者入院后给予基础治疗,对照组患者给予匹多莫德分散片治疗,研究组患者在对照组基础上给予0.1%他克莫司软膏治疗,两组患者均持续治疗3个月。比较两组患者的临床疗效,治疗前后皮损处白介素4(IL-4)及肿瘤坏死因子α(TNF-α)水平及不良反应发生情况。结果研究组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者皮损处IL-4及TNF-α水平比较,差异无统计学意义(P>0.05);治疗后,研究组患者皮损处IL-4及TNF-α水平低于对照组(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论匹多莫德分散片联合0.1%他克莫司软膏治疗白癜风临床疗效肯定,可有效改善患者皮损处炎性反应,且安全性高。

Objective To explore the clinical effect of pidotimod dispersible tablets combined with 0. 1% tacrolimus ointment in treating vitiligo. Methods A total of 140 cases of vitiligo patients were selected from March 2011 to March 2014 in Maternal and Child Health Hospital in Guiyang City of Guizhou Province,which were divided into control group and study group,70 cases in each group. All patients were given conventional therapy,control group was treated with pidotimod dispersible tablets,study group was treated with 0. 1% tacrolimus ointment based on control group,both groups were treated for 3 months. The clinical effect,IL-4,TNF-α before and after treatment and the incidence of adverse reactions were compared between the two groups. Results Study group of clinical effect was better than control group（ P〈0. 05）. Before treatment,no statistically significant differences in IL-4 or TNF-α levels was found between the two groups（ P〉0. 05）; after treatment,the IL-4and TNF-α levels of study group were lower than control group（ P〈0. 05）. No obvious adverse reactions was happened.Conclusion Pidotimod dispersible tablets combined with 0. 1% tacrolimus ointment have an exactly clinical effect in treating vitiligo,it can effectively improve skin lesions inflammation,and with high safety.